



# PDTM Update

Date: February 7, 2025

To: Parenteral Drug Therapy Manual Users at BC Women's Hospital + Health Centre (BCW), Providence Health Care (PHC) and Vancouver Coastal Health (VCH)

From: Parenteral Drug Therapy Manual Support ([pdtm@vch.ca](mailto:pdtm@vch.ca))

The following information has been updated since November 1, 2024 through January 31, 2025; please refer to the on-line manual for the most recent version(s):

Document	Summary of changes
alpha1-proteinase inhibitor (human), highly purified	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, Dosage, Potential Hazards of Parenteral Administration, and Important Implications sections
alprostadil	Updated Compatibility section
amphotericin B liposomal (AMBISOME)	Updated Reconstitution & Stability, Compatibility, Preparation & Administration, Dosage, and Important Implications sections
anakinra	New monograph
aspergillus skin test	Archived
buprenorphine long acting	Updated Reconstitution & Stability, Preparation & Administration, and Potential Hazards of Parenteral Administration sections
clevidipine	New monograph
colistimethate	Updated Compatibility, Preparation & Administration, and Dosage sections
dalbavancin	New monograph
darbepoetin	Updated Reconstitution & Stability, Preparation & Administration, Dosage, and Important Implications sections

## Lower Mainland Pharmacy Services

Document	Summary of changes
degaralix	Name change from degarelix long acting to degarelix
dextrose 50%	Updated Reconstitution & Stability, and Preparation & Administration sections
epcoritamab	New monograph
epoprostenol	Updated Reconstitution & Stability, Compatibility, Preparation & Administration, and Dosage sections
filgrastim	Updated Indications, Reconstitution & Stability, and Important Implications sections
flumazenil	Updated Compatibility, Preparation & Administration, and Important Implications sections
flupenTIXol long acting (was flupenthixol)	Updated Reconstitution & Stability, Preparation & Administration, and Important Implications sections
fosaprepitant	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, Potential Hazards of Parenteral Administration, and Important Implications sections
haloperidol long acting (was haloperidol decanoate)	Updated Reconstitution & Stability, Preparation & Administration, Dosage, and Important Implications sections
histamine	Updated Preparation & Administration, Dosage, and Important Implications sections
hydrocortisone (was hydrocortisone sodium succinate)	Updated Reconstitution & Stability, Compatibility, Preparation & Administration, and Important Implications sections
hydroxocobalamin	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections
idaruCIZUmab	Updated Reconstitution & Stability, Compatibility, and Important Implications sections
ketamine	Updated Preparation & Administration section
levETIRAcetam	Updated Indications, Compatibility, Preparation & Administration, and Dosage sections
levofloxacin	Updated Reconstitution & Stability, Compatibility, and Important Implications sections
levothyroxine	Updated Reconstitution & Stability, Dosage, and Important Implications sections
loxapine	Updated Important Implications section

**Lower Mainland Pharmacy Services**

Document	Summary of changes
methotrimeprazine	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections
methylnaltrexone	Updated Indications, Reconstitution & Stability, Preparation & Administration, and Important Implications sections
methylPREDNISolone acetate long acting	Updated Preparation & Administration, and Important Implications sections  Name change from methylPREDNISolone ACETATE long acting to methylPREDNISolone acetate long acting
micafungin	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, and Important Implications sections
mogamulizumab	New monograph
moxifloxacin	Updated Reconstitution & Stability, Preparation & Administration, Compatibility, and Important Implications sections
NORepinephrine	Updated Preparation & Administration section
ocrelizumab	New monograph
octreotide long acting	Updated Indications, Reconstitution & Stability, Preparation & Administration, Dosage, Potential Hazards of Parenteral Administration, and Important Implications sections
oxytocin	Updated Compatibility, Preparation & Administration, and Dosage sections
paliperidone long acting	Updated Indications, Reconstitution & Stability, and Important Implications sections
pantoprazole	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections
papaverine	Updated Reconstitution & Stability, Compatibility, and Important Implications sections
PHENYLephrine	Updated Preparation & Administration section
rasburicase	Updated Compatibility, Potential Hazards of Parenteral Administration and Important Implications sections
risperidone long acting	Updated Indications and Reconstitution & Stability sections

**Lower Mainland Pharmacy Services**

Document	Summary of changes
scopolamine HYDRObromide	Updated Reconstitution & Stability and Important Implications sections
somatropin	Updated Indications, Reconstitution & Stability, and Important Implications sections
streptomycin	Updated Indications, Compatibility, Preparation & Administration, and Dosage sections
SUFentanil	Updated Indications, Reconstitution & Stability, Compatibility, Preparation & Administration, Dosage, and Potential Hazards of Parenteral Administration, and Important Implications sections
vitamin K (was phytonadione)	Updated Reconstitution & Stability, Compatibility, and Preparation & Administration sections